Skip to content
DataLookout
Menu

NATRIX-BNPNCT06237309

REGN5381 in Adult Participants With Heart Failure With Reduced Ejection Fraction

StatusTerminated
PhasePhase 2
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

Version history last read from ClinicalTrials.gov on Aug 30, 2026. The record was updated there on Nov 19, 2026; versions filed since then are not listed here yet.

All 20 versions: 20 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Results posted: Nov 19, 2026
  2. Stopped Trial status: Active, Not Recruiting to Terminated Sponsor's reason: Sponsor decision
    • Study completion date changed from estimate of Dec 30, 2025 to Dec 29, 2025
    v20
  3. Minor Trial status: Recruiting to Active, Not Recruitingv19 Show 4 more changesShow less
    • Enrollment target: estimated 394 to confirmed 89
    • Primary completion date changed from estimate of Nov 6, 2026 to Sep 17, 2025
    • Study completion date: Feb 17, 2027 to Dec 30, 2025
    • Site details revised at 44 of 44 sites
  4. Notable Primary completion date: Jan 2, 2026 to Nov 6, 2026v18 Show 7 more changesShow less
    • Eligibility criteria expanded, about 13 words
    • Enrollment target: 391 to 394
    • Study sites: 42 to 44
    • Study completion date: Apr 15, 2026 to Feb 17, 2027
    • Secondary endpoints revised (13)
    • Primary endpoint revised
    • Study description expanded, about 11 words
  5. Minor Study sites: 39 to 42v17
Show 15 earlier versionsHide 15 earlier versions
  1. Minor Study sites: 33 to 39v16
  2. Minor Study sites: 24 to 33v15
  3. Minor Study sites: 15 to 24v14
  4. Minor Study sites: 14 to 15v13
  5. Notable Eligibility criteria expanded, about 14 words
    • Study arms: 10 to 12
    v12
  6. Minor Study sites revised (14)v11
  7. Notable Eligibility criteria shortened, about 14 words
    • Study title shortened, about 11 words
    v10
  8. Minor Study sites: 13 to 14v9
  9. Minor Study sites: 12 to 13v8
  10. Minor Study sites: 9 to 12v7
  11. Minor Study sites: 7 to 9v6
  12. Minor Study sites: 6 to 7v5
  13. Minor Study sites: 1 to 6v4
  14. Notable Eligibility criteria expanded, about 25 words
    • Primary completion date: Apr 10, 2026 to Jan 2, 2026
    • Study completion date: Jul 22, 2026 to Apr 15, 2026
    v3
  15. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of May 2, 2024 to Apr 11, 2024
    v2
  1. Study First Submitted
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Fold Change From Baseline in Circulating N-Terminal Pro-Brain Natriuretic Peptide (NTproBNP)
Timeframe: Baseline, Day 8

Secondary (9)

Number of Participants With at Least One Treatment Emergent Adverse Event (TEAE) by Severity
Fold Change From Baseline in Circulating NT-proBNP
Change From Baseline in Systolic Blood Pressure (SBP)
Change From Baseline in Diastolic Blood Pressure (DBP)
Change From Baseline in Mean Arterial Pressure (MAP)
Show 4 moreShow less
Change From Baseline in Heart Rate (HR)
Concentration of Total REGN5381 in Serum
Number of Participants With a Treatment-Emergent Anti-Drug Antibody (ADA) Response to REGN5381
Maximum Titer Category of Participants With ADAs to REGN5381

Arms and interventions

Part A1 High DoseExperimental

Single ascending dose cohort

Part A1 Low DoseExperimental

Single ascending dose cohort

Part A1 OptionalExperimental

Single ascending dose cohort

Part A2 High Dose, sacubitril-valsartan groupExperimental

Single ascending dose cohort

Part A2 Low Dose, sacubitril-valsartan groupExperimental

Single ascending dose cohort

Placebo for Part A2, sacubitril-valsartan groupPlacebo comparator
Part A2 High Dose, Low estimated glomerular filtration rate (eGFR) groupExperimental

Single ascending dose cohort. Note: This group has been closed

Part A2 Low Dose, Low eGFR groupExperimental

Single ascending dose cohort. Note: This group has been closed

Placebo for Part A2, Low eGFR groupPlacebo comparator

Note: This group has been closed

Part B High DoseExperimental
Part B Low DoseExperimental
Part A1 and Part B Placebo OnlyPlacebo comparator

Drugs: REGN5381, Placebo

Sites

44 sites in 12 countries

Belgium 8, Poland 5, Czechia 4, Greece 4, South Africa 4, South Korea 4, Spain 4, United States 4, Bulgaria 3, Romania 2, Georgia 1, Moldova 1